Pfizer Inc ((PFE)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Pfizer Inc. is conducting a study titled ‘Retrospective Cohort Study of Pregnancy Outcomes in Women Exposed to Rimegepant During Pregnancy.’ The study aims to assess the risk of pregnancy and infant outcomes in women with migraines who are exposed to rimegepant during pregnancy, compared to two unexposed groups. This research is significant as it seeks to understand the safety profile of rimegepant, a migraine medication, during pregnancy.
The intervention being tested is the drug Rimegepant, which is used to treat migraines. The study also includes comparator groups exposed to other migraine medications and a group with no intervention.
This is an observational study with a cohort model and a retrospective time perspective. The primary purpose is to evaluate health outcomes without any specific allocation or masking involved.
The study began on December 15, 2021, with an ongoing recruitment status. The latest update was submitted on August 4, 2025. These dates are crucial as they indicate the study’s progress and current status.
For investors, this study could influence Pfizer’s stock performance by potentially expanding the market for rimegepant if the results are favorable. It may also impact investor sentiment positively if the drug is deemed safe for use during pregnancy, setting Pfizer apart from competitors in the migraine treatment market.
The study is ongoing, with further details available on the ClinicalTrials portal.